Some studies have shown that BI2536, Volasertib, and GSK461364 can effectively inhibit the expression of PLK1, and BI2536 has entered phase I clinical trials for colorectal cancer, liver cancer, fallopian duct cancer, and other cancers [43–45]. The gene discussed is PLK1; the disease is liver cancer.